◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral WATCH-LIST MEDIUM

Melatonin (HIGH-DOSE — antioxidant / oncology / neuroprotection use)

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict WATCH-LIST MEDIUM

The mechanism is real and well-characterized — Russel Reiter's life work plus replicated oncology and ICU/sepsis adjunct trials establish high-dose melatonin as a legitimate antioxidant + mitochondrial protectant. For Dylan's specific concern (subconcussive impact load from MMA), the rodent TBI literature is robust and the human-translation evidence is plausibility-tier rather than proven. Verdict is WATCH-LIST rather than STRONG-CANDIDATE because (1) chronic high-dose use in healthy 20-year-old males is essentially unstudied — the pharmacological literature is in cancer patients, ICU patients, and elderly populations where the risk/reward calculus is different; (2) heavy sedation, vivid dreams, and morning grogginess are essentially universal at 20-50+ mg, which conflicts with Dylan's brain-priority value system; (3) HPG-axis caveats — while clinical evidence in young males at supplement doses is reassuring, the data at 50-300 mg chronic dosing is genuinely thin. **The intermittent post-sparring PRN protocol (20-50 mg HS the night of a hard sparring session, ≤2× per week)** is the rational way to capture mechanism-aligned neuroprotection benefit with minimal chronic exposure. Verdict shifts to OPTIONAL-ADD if a credible TBI / subconcussive-impact human RCT lands positive; shifts toward STRONG-CANDIDATE only in a specific recovery context (post-major-illness, post-significant-head-injury). For chronic daily high-dose, verdict stays WATCH-LIST indefinitely absent better human longitudinal safety data in young adults.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    WATCH-LIST

    Mechanism-aligned with subconcussive impact protection thesis. Chronic daily high-dose contraindicated by morning-fog cost + thin chronic-young-male safety data + theoretical HPG-axis concerns. PRN post-sparring protocol (20-50 mg HS, ≤2×/week) is the rational instantiation. Worth a 4-8 use trial after V5 stack stabilizes. Discontinue if morning fog persists or dream content disturbs.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    Mechanism-aligned, but the felt-cost (morning fog) tends to be net-negative unless specific oxidative-stress indication exists (post-illness recovery, post-injury, demanding athletic load). Most users in this archetype do better at low-dose phase-shift protocol than chronic high-dose.

  • 50+, mild cognitive decline / neurodegenerative risk
    STRONG-CANDIDATE

    This is the population the Spanish geriatric trials cover; chronic 50-100 mg/day shows clean 2-year safety, plausible cognitive preservation hypothesis, mechanism-aligned with the oxidative-stress trajectory of aging. The morning-fog cost is more tolerable in non-working populations.

  • Anxiety-prone
    NEUTRAL

    Vivid dreams can include disturbing content; for users with rumination tendencies or trauma history, the dream phenotype can be a meaningful negative.

  • High athletic load, tested status
    NOT

    WADA-banned. No PED concern. PRN post-impact protocol mechanism-aligned. Consideration: morning fog can compromise next-day training; calendar around competition / hard training days.

  • Sleep-disordered (chronic primary insomnia)
    NOT FIRST-LINE

    High-dose melatonin's primary effect is sleep extension + heavy sedation, not classical sleep-onset assistance. Z-drugs, DORAs, trazodone, or low-dose melatonin (melatonin.md) outperform for primary insomnia.

  • DylanSleep-disordered (DSWPD / late chronotype, Dylan's other profile match)
    NOT THIS USE

    see melatonin.md. High-dose 20-50 mg disrupts the phase-shift signal (PRC saturation + plasma persistence into morning). Wrong tool for chronotype migration.

  • Recovery-focused (post-injury, post-illness, post-major-stress)
    STRONG-CANDIDATE

    for short course. This is the use case where mechanism is most clearly indicated and risk-reward calculus is most favorable. 30-50 mg HS for 2-4 weeks post-significant-illness or post-injury is mechanism-aligned and well within the safety envelope.

  • Strength/anabolic-focused
    CAUTION

    at chronic high dose. Theoretical HPG-axis concern is most relevant in this archetype where preserving androgen status matters. PRN intermittent dosing OK; chronic 50+ mg daily is the wrong move for someone optimizing for strength/anabolic output.

  • Cancer / chemotherapy adjunct
    STRONG-CANDIDATE

    Best-evidenced indication for high-dose melatonin. 20-50 mg HS adjunct to standard treatment, oncologist-coordinated.

  • ICU / sepsis / surgical recovery
    STRONG-CANDIDATE

    Emerging A-tier indication. Clinician-administered.

  • Suspected concussion / post-TBI acute
    STRONG-CANDIDATE

    for short course. Mechanism-aligned with mitochondrial preservation in the acute injury window. 50-100 mg HS for 3-7 nights is the defensible protocol. For Dylan specifically: if a "got rocked" event occurs in MMA, this protocol is the most defensible single intervention.

  • Pregnancy / breastfeeding
    AVOID

    unless clinical indication.

  • Bipolar / mania-prone
    CAUTION

    Some literature on melatonin precipitating mania in vulnerable individuals. Not contraindicated but flag.

▸ Subjective experience (deep)

Heavy. Sedating. Vivid. Slow-clearing. This is not the same experience as 0.3-1 mg low-dose.

  • Onset: 30-90 min. Initial drowsiness is more pronounced than at low dose — many users describe "the room dimmed" feeling progressing to genuine sedation, sometimes including mild peripheral vasodilation, hand-warmth, modest hypotension. Some users feel mild euphoria / dissociation in the 60-120 min window before sleep.

  • Sleep: Total sleep time often extended by 1-3 hours vs baseline at 20-50 mg. Sleep onset latency reduced, but mid-sleep awakening 4-6 hours after dose is common (paradoxical wake as exogenous melatonin clears and rebound occurs). Sleep architecture shifts: REM tends to be increased and intensified, contributing to the vivid-dream phenotype.

  • Vivid / hyperreal / sometimes disturbing dreams are essentially universal at ≥20 mg. Dylan should expect this. Reports range from "lucid, beautiful, philosophically interesting" to "dark, intrusive, anxiety-provoking." The psychological character of the dreams is somewhat dose-dependent and somewhat user-specific. Some users genuinely enjoy the dream-experience; others find it disqualifying. The first 1-2 high-dose nights should ideally be on a low-stakes day where Dylan can experiment without anxiety about the dream content.

  • Morning grogginess significant. This is the major downside. At 20-50 mg, morning fog can persist 2-4 hours after waking; at 100+ mg, sometimes the entire morning is compromised. For Dylan, who values morning cognitive performance and has 6-12 hr/day cognitive work, this is the single biggest reason against chronic daily high-dose use. The post-sparring PRN protocol partially mitigates this — intentionally dosing on a night where the next morning has flexibility (e.g., Saturday after Saturday-evening sparring → Sunday morning available for slow recovery).

  • Mood / next-day affect: Variable. Some users report enhanced mood and emotional resilience the next day (consistent with reduced inflammatory load + improved sleep architecture). Others report dampened, flat affect — possibly related to MT receptor desensitization or to the heavy sleep extension shifting circadian rhythm.

  • Hypothermia: Mild core temperature drop is common; at high dose can produce noticeable "feels cold" sensation in the first 60-120 min. Generally benign in healthy adults.

  • Physical sensation post-wake: Many users report a paradoxical "physically refreshed" feel even when cognitively foggy — consistent with the mitochondrial-recovery / antioxidant mechanism. This is the felt-effect Dylan would chase post-sparring: heavy sleep + perceived enhanced physical recovery, accepting the morning fog as the cost.

  • Variability: ~10-15% of users report relatively clean experiences (sedation without major morning fog); ~10-15% report severely disqualifying morning effects. Most fall in the middle. Pharmacogenomic factors (CYP1A2, MTNR1B) probably explain some of the variance.

▸ Tolerance + cycling deep dive
  • Tolerance buildup at PRN intermittent dosing: minimal. The 1×/week frequency is well below any documented tolerance window.
  • Tolerance at chronic daily 20-100 mg dosing: theoretical receptor desensitization at MT1/MT2; not a concern at this dose tier because the receptor-mediated effects are not the goal. The antioxidant / mitochondrial mechanisms do not show classical tolerance.
  • Recommended cycle for Dylan: PRN only, ≤2×/week. No cycling needed; the intermittency IS the cycling.
  • Recommended cycle for chronic high-dose oncology / ICU contexts: continuous through indication; no formal cycling.
  • Discontinuation: No taper required even from chronic high dose. May see 1-3 days of sleep timing wobble; behavioral anchors carry the day.
▸ Stacking deep dive

Synergistic with

  • Astaxanthin (Dylan V5 — 12 mg/day): Both target mitochondrial-membrane oxidative stress; astaxanthin spans the bilayer, melatonin accumulates inside the mitochondrial matrix. Layered protection of inner and outer mitochondrial membrane lipids. Best mechanism-aligned daily-stack pair for Dylan's brain-protection thesis. Same Saturday post-sparring night, plus astaxanthin daily — multi-vector mitochondrial protection.
  • Omega-3 / DHA (Dylan V4 — 2 g DHA): DHA is the most peroxidation-susceptible fatty acid in neuronal membranes; melatonin's mitochondrial scavenging protects DHA from peroxidation in situ. Layered.
  • NAC (Dylan V4 — 1,200 mg/day): NAC supplies cysteine for glutathione synthesis; melatonin upregulates GSS (glutathione synthetase) transcription. Different pathway points, complementary.
  • Curcumin (Dylan V4 — 500 mg phytosome): Both NF-κB suppressors, both NRF2 activators. Some redundancy on the transcriptional side; layered.
  • Glycine (Dylan V4 — 3 g, transitioning to tryptophan in V5): Glycine has its own mitochondrial-glutathione-precursor role + NMDA modulation. No conflict.
  • SS-31 / elamipretide (research peptide, theoretical V6+): Cardiolipin-targeted mitochondrial peptide. Highest mechanism-overlap of any compound — both concentrate at the mitochondrial inner membrane, both protect against mPTP opening, both are antioxidant in the matrix compartment. Theoretical synergy is strong; no clinical data combining them. Research-tier consideration only.
  • Vitamin C (Dylan V4): Aqueous-phase scavenger; complements melatonin's lipid/mitochondrial focus.
  • Magnesium glycinate / magtein (Dylan V4): Mg2+ is required for ATP synthase function and mitochondrial stability; cofactor support for the same compartment melatonin protects. No conflict.

Avoid stacking with

  • High-dose l-tryptophan or 5-HTP on the same night: substrate-flooding the serotonin → melatonin pathway plus exogenous high-dose melatonin = excessive central serotonergic + sedative load. Specific Dylan protocol: skip V5 tryptophan dose on PRN-melatonin nights.
  • Sedative drugs without prescriber sign-off (benzos, Z-drugs, phenibut, GHB, opioids, gabapentinoids, alcohol): additive sedation, additive hypothermia, additive hypotension. High-dose melatonin's sedation profile is meaningful — adding another CNS depressant compounds risk.
  • Fluvoxamine (CYP1A2 inhibitor): plasma melatonin AUC ↑ 17-23× — at 20 mg oral with fluvoxamine, plasma levels could approach the 300 mg dose tier. Avoid combo or use far lower dose with monitoring.
  • Ciprofloxacin and other strong CYP1A2 inhibitors: similar concern, smaller magnitude.
  • Oral contraceptives / estrogens: mild CYP1A2 inhibition; modest exposure increase. Not a hard contraindication.
  • Warfarin / DOACs: case reports of enhanced anticoagulation; INR monitoring if combined.
  • Immunosuppressants (cyclosporine, tacrolimus): theoretical immune-modulation interaction; caution at high dose. Not relevant to Dylan.
  • Antihypertensives: additive hypotensive effect at high dose. Not relevant to Dylan (normotensive).
  • Bright light during plasma elevation window: light exposure attenuates melatonin's signaling and may modulate antioxidant effects. Use dark/dim environment for the 4-6 hours post-dose.

Neutral / safe co-administration

  • All V4 daily core items at PRN dosing nights: NAC, citicoline, magnesium glycinate, magtein, PS, curcumin, rhodiola, theanine, D3+K2, beta-alanine, vitamin C, glycine, DHA — no PK or PD conflicts at the intermittent PRN dose.
  • All V5 AM-dosed items (modafinil, bromantane, Adamax, ALCAR, apigenin, taurine, astaxanthin) — temporal separation precludes interaction.
  • Caffeine: cutoff 10+ hr pre-bed regardless. Both CYP1A2 substrates but no meaningful interaction at supplement doses.
  • Creatine, beta-alanine: no interaction.
  • Cerebrolysin (cycled, IM): different mechanism, no PK interaction.
▸ Drug interactions deep dive
Interactor Effect Magnitude Action
Fluvoxamine (Luvox) Strong CYP1A2 inhibition Plasma melatonin AUC ↑ 17-23× Avoid combo at high dose; if both required, drastically reduce melatonin and monitor sedation
Ciprofloxacin, enoxacin, norfloxacin CYP1A2 inhibition Moderate-significant exposure increase Caution; consider lower dose during course
Oral contraceptives, estrogens Mild CYP1A2 inhibition Modest elevation Awareness; rarely clinically meaningful at PRN dose
Cigarette smoking CYP1A2 induction Reduces exposure May need higher dose; not relevant for Dylan (non-smoker)
Warfarin / DOACs Possible additive anticoagulant effect Variable, case reports of bleeding INR monitoring if combined
Immunosuppressants (cyclosporine, tacrolimus) Theoretical immune modulation Unclear Caution at high dose
Antihypertensives / beta-blockers Additive hypotension at high dose Pharmacodynamic Awareness; not relevant for Dylan
CNS depressants (benzos, Z-drugs, alcohol, opioids, phenibut) Additive sedation, hypothermia, hypotension Variable Avoid double-stacking
Modafinil Mild CYP1A2 induction at chronic dose Minor reduction in melatonin exposure Not a concern at PRN dose; possibly mildly reduces effect
Caffeine Both CYP1A2 substrates Minor competitive Safe at typical timing
L-tryptophan / 5-HTP at same time Additive serotonergic / sedative load Variable Skip same-night dosing
SSRIs / SNRIs Theoretical additive central serotonergic load Weak clinical signal Awareness; not contraindicated

CYP enzymes: Melatonin primarily metabolized by CYP1A2 (~90%) to 6-hydroxymelatonin → urinary 6-sulfatoxymelatonin. Minor: CYP2C19, CYP2C9. Melatonin does not significantly induce or inhibit CYPs at supplement doses; interactions are one-way (other drugs affect melatonin, not vice versa).

Practical for Dylan: No current V4/V5 medication has a meaningful interaction at the PRN protocol dose. Modafinil is a mild CYP1A2 inducer at 100 mg chronic — if Dylan finds his post-sparring melatonin effect is mildly attenuated after V5 modafinil onboarding, increase melatonin dose modestly (30 → 50 mg).

▸ Pharmacogenomics
  • *CYP1A2 1F (rs762551) — high-inducibility allele (~60% Caucasian frequency): *1F homozygotes clear melatonin faster, may need higher dose for similar plasma exposure. Dylan's Nordic ancestry increases base-rate likelihood.
  • *CYP1A2 1C (rs2069514) — reduced-activity allele: higher exposure at standard doses; lower dose sufficient.
  • MTNR1B rs10830963 (G allele): largely irrelevant at high dose because MT1/MT2 are saturated; matters for low-dose phase-shift use (melatonin.md).
  • MTNR1A SNPs: low relevance at high dose.
  • NQO2 polymorphisms: theoretical relevance for the MT3/NQO2 detoxification pathway; not clinically actionable.
  • APOE4: theoretical interest for high-dose melatonin in neurodegenerative-risk individuals, since APOE4 oxidative stress is melatonin-target-aligned. No human stratified data exists. If Dylan's 23andMe (June 2026) returns APOE4, the rationale for occasional high-dose melatonin strengthens modestly (from "mechanism-aligned plausibility" to "mechanism-aligned plausibility plus genetic indication"). Dose unchanged.
  • Practical action for Dylan after 23andMe (June 2026):
    • Pull CYP1A2 rs762551: *1F homozygous → may benefit from 50 mg over 30 mg in PRN protocol.
    • Pull APOE genotype: APOE4 carrier → mild upgrade in rationale, doesn't change dose tier.
    • No CPIC guideline for melatonin exists; data is suggestive, not prescriptive.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
iHerb Life Extension Melatonin 10 mg (60 ct) $10-15/bottle HIGH Top OTC pick for Dylan's PRN protocol. Clean COA history; combine 2-5 caps for 20-50 mg PRN dose. ~$0.20-0.30 per PRN use.
iHerb NOW Foods Melatonin 20 mg (60 ct) $15-22/bottle HIGH Higher per-cap dose; convenient for 20-40 mg PRN dose. Same iHerb V4/V5 channel.
iHerb Pure Encapsulations Melatonin 3-20 mg $20-35/bottle HIGH NSF-tested; premium. Overkill for PRN.
Amazon Various 5-30 mg $5-15 LOW-MEDIUM Avoid for the same reason as low-dose melatonin.md: Cohen 2023 J Clin Sleep Med — 88% of US melatonin gummies mislabeled, range 74-347% of label. Mass-market quality control is genuinely worse than for most supplements. Some pill-form Natrol / Nature Made / Costco Kirkland 5-10 mg are acceptable but per-dose for PRN protocol still lower-confidence than iHerb.
Compounding pharmacy Custom 50-300 mg melatonin capsules $50-100/month for chronic; per-prescription for PRN HIGH Required for >50 mg single doses. Telehealth Rx (Push Health, Hone, ad-hoc telehealth) can access; some compounding pharmacies fill on Rx for off-label oncology / cluster headache / TBI rationale. Not strictly necessary for Dylan's PRN protocol if 20-50 mg is the operating range.
Bulk powder Bulk Supplements melatonin powder $10-20 for 50 g MEDIUM-HIGH Cheap; useful for high-dose users who don't want to pop 5+ caps. Requires accurate scale (mg-precision). Dose-mismeasurement risk. Not recommended for Dylan unless he wants the chronic-high-dose route.
EU pharmacy Circadin 2 mg PR (Rx EU/UK/AU) $40-80/month HIGH Wrong form (prolonged-release at low dose); not relevant.
iHerb (low-dose reference, NOT this file) Life Extension 300 mcg / 500 mcg $5-12/bottle HIGH This is the dose for the OTHER use case — see melatonin.md for phase-shift protocol. Mentioned here for clarity.

Practical sourcing for Dylan (US, PRN protocol):

  • Recommended primary: Life Extension Melatonin 10 mg from iHerb. Same V4/V5 vendor channel. Combine 2-5 caps for 20-50 mg PRN dose. ~$10-15 buys 60 caps = 30+ PRN doses = ~6 months at 1×/week.
  • Alternative: NOW Foods 20 mg from iHerb — cleaner pill count for 20-40 mg dosing.
  • For occasional 100+ mg single-dose post-impact protocol: combine 5-10 caps of 10 mg or use NOW 20 mg × 5; or fill compounding pharmacy 100 mg cap for specific event-triggered use.
  • Stay off Amazon for melatonin specifically. Cohen 2023 quality-control problem applies regardless of dose tier.

Estimated cost for Dylan's PRN protocol: ~$2-4/month amortized. Negligible. The dominant cost-question is not dollars but morning-fog opportunity-cost.

▸ Biomarkers to track (deep)

Baseline (before starting PRN protocol)

  • June 2026 baseline panel (already scheduled for Dylan): CMP, lipid panel, hsCRP, HbA1c, full thyroid panel, CBC, LH, FSH, total + free testosterone, SHBG, morning cortisol, 25(OH)D, ferritin, B12, folate.
  • Optional oxidative stress markers: MDA, 8-OHdG, oxidized LDL, GPx activity, SOD activity, GSH/GSSG ratio. Most through specialty labs (Genova ION Profile, Doctor's Data oxidative stress panel). Useful if Dylan wants to formally measure delta from PRN protocol.
  • Optional TBI / neuroinflammation markers: Serum NfL (neurofilament light), S100B, GFAP. NfL is the most robust subconcussive-impact biomarker; available via Quanterix Simoa or Olink. High-leverage measurement for Dylan's specific brain-protection thesis — if NfL drops measurably with PRN protocol, that's strong evidence the mechanism is translating to him personally. Not cheap (~$200-500/measurement), so reserve for serious experimentation.
  • Subjective: Sleep duration, morning alertness 1-10, post-sparring "feel" 1-10, dream-content log.
  • Wearable: Colmi R06 ring sleep timing + duration data already running.

During use

  • Every PRN use: Sleep duration (Colmi), morning alertness 1-10, dream content category (interesting/neutral/disturbing), next-day cognitive output 1-10, next-day mood 1-10.
  • After 4-8 PRN uses: Compare averages to non-PRN-night baseline. Decision point: net-positive, net-neutral, net-negative on perceived recovery.
  • Every 6 months if continuing PRN: LH, FSH, total + free T, hsCRP, lipid panel, CMP. Compare to pre-PRN baseline.

Annual / longitudinal

  • Annual bloodwork: full panel.
  • NfL / S100B optional if Dylan wants formal subconcussive-impact tracking — separate from melatonin-specific.
  • Every 12-18 months reassess protocol: is PRN still useful? Has his MMA training schedule changed? New evidence published on TBI / subconcussive RCTs?
▸ Controversies / open debates Live debate

  1. The Reiter dose claim — real or overhyped? Russel Reiter is the most influential melatonin antioxidant researcher; his 700+ papers establish the mechanism. Critics note: (a) much of his work is in rodents at human-equivalent doses far above clinical use; (b) Reiter has authored or co-authored a substantial fraction of the high-dose melatonin literature, raising single-investigator concentration concerns; (c) the "1 melatonin = 4 ROS" cascade calculation is mechanistically real but somewhat idealized — actual stoichiometric efficiency in vivo is harder to measure. Net: mechanism is real, magnitude in healthy young humans is uncertain.

  2. Lissoni oncology data — real signal or single-investigator artifact? Most oncology adjunct melatonin RCTs come from Paolo Lissoni's group in Italy. Subsequent meta-analyses including non-Lissoni trials confirm direction of effect (modest mortality reduction, reduced chemo toxicity) but at smaller effect size. Net: oncology indication is supported but evidence base is weaker than the 2,000-patient meta would suggest at face value.

  3. HPG-axis concern at chronic high dose in young males — real but understudied. The Voordouw 1992 LH-pulsatility data is old, the dose was very high (75-300 mg in young women), and the population was different. There is no published data on chronic 50+ mg melatonin in young males with serial T/LH/FSH measurement. Reasonable assumption based on geriatric Spanish data plus mechanism: chronic high-dose probably has some HPG-axis effect, magnitude unclear, more relevant to Dylan than to a 70yo. Argues for intermittent PRN protocol over chronic daily.

  4. TBI human translation — the central evidence gap for Dylan. Animal data is robust and replicated. Small human pilot trials (Seifman, Rezaei) suggest reduced oxidative stress markers and possibly improved outcomes in moderate-severe TBI. No published RCT in subconcussive-impact athletes. A high-leverage trial would be: NCAA football / boxing / MMA cohort, 50 mg HS PRN post-impact vs placebo, NfL + S100B + cognitive testing endpoints. Doesn't yet exist. For Dylan, the right framing is: "mechanism-aligned bet on a hypothesis with strong animal data, awaiting human translation."

  5. Receptor desensitization concern in chronic supraphysiological dosing — debated. 2005-2015 era literature was alarmist; 2020-2025 era literature is more measured. Endogenous pineal melatonin output does not appear to be downregulated by short courses of exogenous melatonin in humans at standard supplement doses. The concern at 50+ mg chronic remains theoretical. For PRN intermittent protocol: essentially zero concern. For chronic daily 50+ mg in young adults: still under-characterized.

  6. COVID-era usage (FLCCC) — methodology contamination. The 2020-2023 explosion of high-dose melatonin use in COVID protocols generated a lot of clinical experience but the literature is contaminated by protocol heterogeneity (ivermectin, hydroxychloroquine, vitamin D, zinc co-administration). Useful as broad safety reassurance at the 20-50 mg dose tier in adult populations; less useful for evaluating melatonin's specific contribution to outcomes.

  7. Chronic high-dose vs intermittent PRN — the central protocol question. Most published trials are continuous chronic dosing (4-12 weeks oncology adjunct, 2 years geriatric). The intermittent-PRN approach Dylan would adopt is essentially un-trialed. The mechanistic argument for intermittent dosing is decent (acute oxidative stress events are when antioxidant capacity is most needed) but is not formally validated.

  8. Dose-saturation curve. Above ~20-50 mg, additional dose probably produces diminishing antioxidant returns due to plasma saturation kinetics + receptor desensitization + diminishing transcriptional effect. The 100-300 mg dose tier is mostly relevant for specific acute events (post-stroke, post-TBI, post-major-illness) where maximum acute scavenging matters. For Dylan's PRN protocol, 20-50 mg is the operating range; 100 mg only for unusual events.

  9. Melatonin as hormone vs drug — regulatory ambiguity. US OTC status reflects historical accident, not pharmacological rationale. EU Rx-only status is more pharmacologically appropriate. The American consumer market has normalized doses (5-10 mg gummies) that no clinical trial supports for sleep, while making physiological-dose (0.3 mg) products and high-dose (50+ mg) products both relatively niche. The market is mis-calibrated; sourcing intentionally is required.

  10. Hormesis and antioxidant overload. A real critique of the heavy-antioxidant biohacker stack is that excessive antioxidant load impairs the body's adaptive hormesis response — the same mechanism applies to vitamin E in athletes, vitamin C blunting training adaptations, etc. Argues for intermittent rather than continuous high-dose use in any antioxidant.

▸ Verdict change log
  • 2026-05-06 — Initial verdict: WATCH-LIST, MEDIUM confidence. High-dose melatonin (20-300 mg) is mechanism-aligned with Dylan's subconcussive impact protection thesis: direct hydroxyl-radical scavenging via the AFMK/AMK cascade (~4 ROS per melatonin), mitochondrial accumulation at ~100× plasma, NRF2 / SIRT1 transcriptional upregulation. A-tier human evidence in oncology adjunct (Mills 2005 meta n=2,000+), ICU/sepsis (MELODY pilot, Galley 2014), neonatal HIE. Robust rodent TBI literature (Reiter/Bondy line); human translation thin. Verdict NOT STRONG-CANDIDATE because (a) chronic daily high-dose in healthy 20yo males is essentially unstudied; (b) heavy sedation + morning grogginess + vivid dreams conflict with brain-priority value system; (c) HPG-axis caveats real at chronic high dose despite reassuring PRN data. Rational instantiation for Dylan: intermittent PRN protocol — 20-50 mg HS the night of hard sparring sessions, ≤2×/week. Captures mechanism benefit with minimal chronic exposure. Verdict shifts to OPTIONAL-ADD if a credible TBI/subconcussive RCT lands positive; shifts toward STRONG-CANDIDATE in specific recovery contexts (post-major-illness, post-significant-head-injury). For chronic daily high-dose, verdict stays WATCH-LIST indefinitely absent better young-adult longitudinal safety data.
▸ Open questions / gaps Open
  1. Will a subconcussive-impact / TBI human RCT in athletes land before Dylan's MMA career intensifies? No published as of 2026-05-06; awaiting. Highest-leverage piece of new evidence for this verdict.
  2. 23andMe results (June 2026): APOE4 status, CYP1A2 *1F status — modulate dose tier and rationale strength.
  3. Dylan's NfL baseline + serial measurement: if Dylan formally measures NfL pre-PRN-protocol and after 8-12 PRN uses, that would be the cleanest possible n=1 evaluation. Cost ~$200-500/measurement; defensible if protocol is being seriously evaluated.
  4. PRN vs chronic — does intermittent capture mechanism benefit? Mechanistic argument decent; not formally validated. If Dylan's NfL or hsCRP drops measurably with PRN protocol, supports intermittent thesis.
  5. Chronic safety in young males at 50+ mg/day: missing data. Unlikely to be filled — no commercial sponsor for that trial. Argues for staying off chronic daily protocol absent specific clinical indication.
  6. Compatibility with V5 modafinil + bromantane onboarding: PRN protocol postpones until V5 stack is stable (8-12 weeks post-modafinil onboarding). Don't add high-dose melatonin during stack-titration window.
  7. Stack-positioning vs astaxanthin: Astaxanthin daily handles routine mitochondrial-membrane antioxidant load; high-dose melatonin handles acute post-impact spikes. Layered roles. No reason to substitute one for the other.
  8. Cerebrolysin cycles + high-dose melatonin: Theoretical synergy (Cerebrolysin is also neuroprotective via different mechanism — neurotrophic signaling). No published combination data. If Dylan adopts both, run them on different schedules to avoid confounding.
▸ Sources (full, with our context)

Mechanism — the Reiter / Acuña-Castroviejo / Tan canon

Oncology adjunct

ICU / sepsis / surgical

Neonatal HIE

TBI — animal + small human

COVID-era high-dose data

Long-term safety at high dose

HPG-axis / fertility / hormone considerations

Pharmacokinetics / interactions

Sourcing

Encyclopedia + cross-references

  • ./melatonin.md — low-dose phase-shift / sleep-onset / DSWPD use case (Dylan's STRONG-CANDIDATE V5 indication).
  • ./astaxanthin.md — daily mitochondrial-membrane antioxidant (V5 daily core).
  • ./n-acetyl-cysteine.md — V4 daily glutathione-precursor antioxidant.
  • ./curcumin.md — V4 daily NRF2 / NF-κB modulator.
  • ./methylene-blue.md — alternative mitochondrial-targeted compound.
  • ./ss-31.md — research-tier cardiolipin-targeted mitochondrial peptide.
  • ../NOOTROPICS-ENCYCLOPEDIA-2026-05-05.md — V5 stack reference.
  • ../_PROFILES/dylan.md — primary user profile, MMA / subconcussive impact context.
Back to compact view